BerGenBio

BerGenBio ASA: Exercise of share options and increase of share capital

Bergen, Norway, 28 June 2019: BerGenBio ASA (the "Company") (OSE: BGBIO) today

announces that in order to to fulfil the Company's obligations under its option

scheme, the Board of Directors has resolved to increase the Company's share

capital by NOK 9,000 by issuance of 90,000 new shares. The new shares have been

issued to an existing option owner entitled to exercise options in accordance

with the Company's option scheme. The subscription price is in accordance with

the prevailing options price pursuant to the Company´s option scheme, in average

NOK 10.91 per share.

The capital increase is expected to be registered within 7 days, and following

the issuance of the new shares, the issued share capital of BerGenBio ASA will

be NOK 6,053,659 consisting of 60,536,590 shares, each with a par value of NOK

0.10.

-End-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie

CFO, BerGenBio ASA

+47 917 86 513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the

expectations expressed or implied in this announcement by such forward-looking

statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

AI Terminal